Table 1. Overview of characteristics and... | American Society of Hematology

Table 1.

Overview of characteristics and outcomes for PFS and OS (rates at 36, 48, and 72 months) for targeted therapy groups from CLL frontline phase 3 trials for all patients and for genetic subgroups (uIGHV, mIGHV, 17p−/TP53mut)

Trial treatment no. of patients	Characteristics (median, if not indicated otherwise)		Estimate at month	PFS rate (%)				OS rate (%)
Trial treatment no. of patients	Characteristics (median, if not indicated otherwise)		Estimate at month	All patients	uIGHV	mIGHV	17p− and/or TP53mut	All patients	uIGHV	mIGHV	17p− and/or TP53mut
RESONATE-2 Ibr n = 136	FU: 60	Age: 73	36	82^a	82^a	83^a		88^a
	CIRS > 6: 31%		48	74^a	75^a	80^a		86^a
	CrCl < 60 mL/min: 44%		72	62^a	62^a	67^a		77^a
iLLUMINATE Obi-Ibr n = 113	FU: 46	Age: 70	36	79	70^a	90^a		86
	CIRS: 4	CrCl: 72	48	74	67	89		82
			72
ALLIANCE Ibr n = 182	FU: 55	Age: 71	36	82	82	84	78	89	89	86	83
		CrCl: 69	48	76	73	84	73	85	85	86	83
			72
ALLIANCE R-Ibr n = 182	FU: 55	Age: 71	36	81	70	83	80	89	84	88	85
		CrCl: 67	48	76	66	78	80	86	82	84	81
			72
ECOG 1912 R-Ibr n = 354	FU: 71	Age: 58	36	89	90	88	85^b	99	99	97	96^b
		CrCl: 95	48	83	83	87	77^b	97	98	97	92^b
			72	72	68	77	51^b	93	93	92	87^b
FLAIR R-Ibr n = 384	FU: 53	Age: 63	36	90	88^a	92^a		95
		CrCl: 79	48	86	88	92	67^b	92
			72	67				89
ELEVATE-TN Acala n = 179	FU: 75	Age: 70	36	84				92
		CrCl: 75	48	78	77	81	76	88
			72	62	60		56	76	76		72
ELEVATE-TN Obi-Acala n = 179	FU: 75	Age: 70	36	92				95
		CrCl: 77	48	87	86	89	75	93
			72	78	75		56	84	84		68
SEQUOIA Zanu n = 241	FU: 44	Age: 70	36	84	82	87		91	89	93
			48	79	72	86		88	85	93
			72
CLL14 Obi-Ven n = 216	FU: 76	Age: 72	36	82	82	86	63	89	89	91	80
	CIRS: 9	CrCl: 65.2	48	74	69	85	54	85	83	89	72
			72	53	43	72	22	79	78	82	60
CLL13 Obi-Ven n = 229	FU: 51	Age: 62	36	89	84	94	n.a.	97	96	97	n.a.
	CIRS: 2	CrCl: 86.3	48	82	74	92	n.a.	95	94	97	n.a.
			72
GLOW Ibr-Ven n = 106	FU: 57	Age: 71	36	79	72^a	90^a		90^a
	CIRS: 9	CrCl: 66.5	48	70	63^a	90^a		86^a
			72
FLAIR Ibr-Ven n = 260	FU: 44	Age: 62	36	97				98	99	96
		CrCl: 83	48	94				95
			72

Trial treatment no. of patients	Characteristics (median, if not indicated otherwise)		Estimate at month	PFS rate (%)				OS rate (%)
Trial treatment no. of patients	Characteristics (median, if not indicated otherwise)		Estimate at month	All patients	uIGHV	mIGHV	17p− and/or TP53mut	All patients	uIGHV	mIGHV	17p− and/or TP53mut
RESONATE-2 Ibr n = 136	FU: 60	Age: 73	36	82^a	82^a	83^a		88^a
	CIRS > 6: 31%		48	74^a	75^a	80^a		86^a
	CrCl < 60 mL/min: 44%		72	62^a	62^a	67^a		77^a
iLLUMINATE Obi-Ibr n = 113	FU: 46	Age: 70	36	79	70^a	90^a		86
	CIRS: 4	CrCl: 72	48	74	67	89		82
			72
ALLIANCE Ibr n = 182	FU: 55	Age: 71	36	82	82	84	78	89	89	86	83
		CrCl: 69	48	76	73	84	73	85	85	86	83
			72
ALLIANCE R-Ibr n = 182	FU: 55	Age: 71	36	81	70	83	80	89	84	88	85
		CrCl: 67	48	76	66	78	80	86	82	84	81
			72
ECOG 1912 R-Ibr n = 354	FU: 71	Age: 58	36	89	90	88	85^b	99	99	97	96^b
		CrCl: 95	48	83	83	87	77^b	97	98	97	92^b
			72	72	68	77	51^b	93	93	92	87^b
FLAIR R-Ibr n = 384	FU: 53	Age: 63	36	90	88^a	92^a		95
		CrCl: 79	48	86	88	92	67^b	92
			72	67				89
ELEVATE-TN Acala n = 179	FU: 75	Age: 70	36	84				92
		CrCl: 75	48	78	77	81	76	88
			72	62	60		56	76	76		72
ELEVATE-TN Obi-Acala n = 179	FU: 75	Age: 70	36	92				95
		CrCl: 77	48	87	86	89	75	93
			72	78	75		56	84	84		68
SEQUOIA Zanu n = 241	FU: 44	Age: 70	36	84	82	87		91	89	93
			48	79	72	86		88	85	93
			72
CLL14 Obi-Ven n = 216	FU: 76	Age: 72	36	82	82	86	63	89	89	91	80
	CIRS: 9	CrCl: 65.2	48	74	69	85	54	85	83	89	72
			72	53	43	72	22	79	78	82	60
CLL13 Obi-Ven n = 229	FU: 51	Age: 62	36	89	84	94	n.a.	97	96	97	n.a.
	CIRS: 2	CrCl: 86.3	48	82	74	92	n.a.	95	94	97	n.a.
			72
GLOW Ibr-Ven n = 106	FU: 57	Age: 71	36	79	72^a	90^a		90^a
	CIRS: 9	CrCl: 66.5	48	70	63^a	90^a		86^a
			72
FLAIR Ibr-Ven n = 260	FU: 44	Age: 62	36	97				98	99	96
		CrCl: 83	48	94				95
			72

Estimates from survival curve.

Sole TP53 mutation; empty fields = data not available.

Acala, acalabrutinib; Age, age in years; CrCl, creatinine clearance in mL/min; FU, median follow-up time in months; Ibr, ibrutinib; n.a., not applicable as 17p− and TP53mut were excluded; Obi, obinutuzumab; R, rituximab; Ven, venetoclax; Zanu, zanubrutinib.

View Large

This Feature Is Available To Subscribers Only